22nd Annual Update in Alzheimer’s Disease and Related Dementias

Register Now

Advance registration is required and will close on Monday, Oct. 28 2024; earlier if capacity is reached.

Wisconsin Alzheimer’s Institute and Wisconsin Alzheimer’s Disease Research Center staff:
Complimentary registration is available for faculty and staff of event sponsors. Contact us if you need access to the staff registration form.

Cancellations/Refund Policy

Requests for cancellation must be submitted in writing to Ryan Browne at rbrowne@wisc.edu. Cancellations on or prior to Monday, Oct. 28, 2024, will be subject to a $50 administrative fee. No registration refunds will be given after Monday, Oct. 28, 2024.

Friday, Nov. 8
Annual Update in Alzheimer’s Disease and Related Dementias
In-Person Conference
8 a.m.–4:30 p.m. CDT
Madison, WI

Thursday, Nov. 7
WAI-Affiliated Dementia Diagnostic Clinic Network Fall Meeting
Hybrid meeting
Open only to members of the WAI-Affiliated Dementia Diagnostic Clinic Network
1:45–5 p.m. CDT

Faculty
Paris Adkins-Jackson, PhD, MPH
Sanjay Asthana, MD, FACP
Barbara Bendlin, PhD, MA
Cynthia Carlsson, MD, MS
Beth Fields, PhD, OTR/L, BCG
Jana E. Jones, PhD
Mary Kerwin, MSSW, APSW
Meghan K. Mattos, PhD, RN
Brian Patterson, MD, MPH
David A. Wolk, MD, FAAN

Planning Committee
Tammi Albrecht, DNP, AGPCNP, APNP, WAI Nurse Practitioner Consultant
Claire Bitner, BA, WAI Communication Specialist
Cynthia Carlsson, MD, MS, Professor of Medicine, WAI Director
Ryan Browne, MFA, WAI Events, Onboarding and Logistics Coordinator
Naveena Jaspal, BA, WAI Marketing Specialist
Sarah Klein, BA, WAI Administrator
Jody Krainer, MSW, LCSW, MBA, WAI Dementia Diagnostic Clinic Network Manager
Maria Mora Pinzon, MD, MS, FACPM, Assistant Professor
Art Walaszek, MD, Professor of Psychiatry, WAI Education and Public Health Leader

Policy on Faculty and Sponsor Disclosure

It is the policy of the Wisconsin Medical Society that the faculty, authors, planners, and other persons who may influence content of this continuing education (CE) activity disclose all relevant financial relationships with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All planners and faculty for this activity have made proper disclosure and any identified relevant financial relationships with ineligible companies have been mitigated. Faculty must also disclose any planned discussion of unlabeled/unapproved uses of drugs or devices during their presentation(s).

Faculty and Planner Disclosures

Name                                                                              Role

Paris Adkins-Jackson,PhD, MPH                               Faculty
Disclosure: Has no relevant relationship(s) with ineligible companies to disclose

Tammi Albrecht, DNP, AGPCNP, APNP                   Planner, Reviewer
Disclosure: Has no relevant relationship(s) with ineligible companies to disclose.

Sanjay Asthana, MD, FACP                                           Faculty
Disclosure: Dr. Asthana, faculty for the educational event, serves as an editor for Hazzard’s Geriatrics and Gerontology, McGraw Hill, Publisher; and is the site Principal Investigator (PI) for a research grant from Genetech Inc. (Study #WN29922) and for a research grant from Toyama Chemical.
All relevant financial relationships with ineligible companies have been mitigated.

Barbara Bendlin, PhD, MA                                             Faculty
Disclosure: Dr. Bendlin has an Advisory Board role with New Amsterdam Pharma, with Cognito Therapeutics, and with Merry Life Biomedical Company, Ltd.
All relevant financial relationships with ineligible companies have been mitigated.

Claire Bitner, BA                                                             Planner
Disclosure: Has no relevant relationship(s) with ineligible companies to disclose.

Ryan Browne, MFA                                                         Planner
Disclosure: Has no relevant relationship(s) with ineligible companies to disclose.

Cynthia Carlsson, MD, MS                                           Course Director, Planner, Faculty, Reviewer
Disclosure: Dr. Carlsson is the site Principal Investigator (PI) for the NIH Alzheimer’s Clinical Trial Consortium (ACTC) AHEAD 3-45 study (sponsored by both NIH and Eisai Inc.); for the Bristol Myers Squibb study evaluating anti-tau therapy; for Ionis Pharmaceuticals study evaluating an ASO therapy to prevent Alzheimer’s in persons with Down syndrome; and for the NIH Alzheimer’s Clinical Trial Consortium (ACTC) START Study (sponsored by both NIH and Cognition Therapeutics).  Dr. Carlsson was the site Principal Investigator (PI) for the NIH Alzheimer’s Clinical Trial Consortium (ACTC) A4 study,(sponsored by both NIH and Eli Lilly) studying solanezumab for Alzheimer’s prevention, the study ended 2023. Dr. Carlsson’s involvement in the VA-funded clinical trial using Amarin Corp. study medications ended when the study was completed in 9/2023.
All relevant financial relationships with ineligible companies have been mitigated.

Beth Fields, PhD, OTR/L, BCG                                      Faculty
Disclosure:  Has no relevant relationship(s) with ineligible companies to disclose.

Naveena Jaspal, BA                                                             Faculty
Disclosure: Has no relevant relationship(s) with ineligible companies to disclose.

Jana E. Jones, PhD                                                              Faculty
Disclosure: Has no relevant relationship(s) with ineligible companies to disclose.

Mary Kerwin, MSSSW, APSW                                            Faculty
Disclosure: Has no relevant relationship(s) with ineligible companies to disclose.

Sarah Klein, BA                                                                      Planner
Disclosure: Has no relevant relationship(s) with ineligible companies to disclose.

Jody Krainer, MSW, LCSW, MBA                              Activity Director, Planner, Reviewer
Disclosure: Has no relevant relationship(s) with ineligible companies to disclose.

Meghan K. Mattos, PhD, RN                                                Faculty
Disclosure: Has no relevant relationship(s) with ineligible companies to disclose.

Maria Mora Pinzon, MD, MS, FACPM                            Planner, Faculty, Reviewer
Disclosure: Has no relevant relationship(s) with ineligible companies to disclose.

Brain Patterson, MD, MPH                                                  Faculty
Disclosure: Has no relevant relationship(s) with ineligible companies to disclose.

David A. Wolk, MD, FAAN                                                    Faculty
Disclosure: Dr. Wolk is the site Principal Investigator (PI) for a research grant from Biogen; he has a consult role with Eily Lily and with Beckman Coulter; and he is on the Data and Safety Monitoring Board (DSMB) for GlaxoSmithKline (GSK) and for Functional Neuromodulation.
All relevant financial relationships with ineligible companies have been mitigated.

Art Walaszek, MD                                                              Faculty, Planner, Reviewer
Disclosure: Has no relevant relationship(s) with ineligible companies to disclose.

All relevant financial relationships with ineligible companies have been mitigated.

Statement of Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Wisconsin Medical Society and Wisconsin Alzheimer’s Institute. The Wisconsin Medical Society is accredited by the ACCME to provide continuing medical education for physicians.

AMA Credit Designation Statement

The Wisconsin Medical Society designates this live activity for a maximum of 2.75 AMA PRA Category 1 Credit(s)™ for Thursday’s WAI-Affiliated Dementia Diagnostic Clinic Network hybrid meeting and a maximum of 6.0 AMA PRA Category Credit(s)™ for Friday’s in-person conference. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Learning Objectives

• Identify cutting-edge approaches to the diagnosis of Alzheimer’s dementia and related disorders across diverse communities
• Describe evidence-based, culturally tailored care management strategies for patients with cognitive disorders
• Identify effective strategies to support and engage caregivers of persons living with dementia

Elements of Competence

This activity has been designed to change learner competence and focuses on the American Board of Medical Specialties areas of medical knowledge, and patient care and procedural skills. This activity also focuses on the interprofessional competencies of roles/responsibilities and teams/teamwork.

Statement of Need

It is estimated 6.9 million Americans aged 65 and older are currently living with Alzheimer’s dementia, and additional 5-7 million of older Americans may have mild cognitive impairment due to Alzheimer’s disease. It is anticipated the aging baby-boom generation will bring the estimate to 13.8 Americans aged 65 and older living with Alzheimer’s dementia by 2060. Alzheimer’s disease is the seventh-leading cause of death in the United States. As a result, there is a heightened need for researchers, healthcare professionals and policymakers to prevent and address the increasing prevalence of Alzheimer’s disease and related dementia in an aging society.
                    – Source: 2024 Alzheimer’s Disease Facts and Figures, Alzheimer’s Association

ADA Compliance Statement

The University of Wisconsin provides equal opportunities in employment and programming, including Title IX requirements. The University of Wisconsin School of Medicine and Public Health complies with the legal requirements of the ADA and the rules and regulations thereof. If any participant in this education activity is in need of accommodations, notify Ryan Browne to receive service. Please call Ryan Browne at (608) 263-3986 or email rbrowne@wisc.edu.

Conference Venue

Discovery Building
330 N. Orchard Street
Madison, WI 53715
(608) 316-4534

Parking: On campus parking can be challenging, hence, in-person attendees should plan time to find parking and to walk to the Discovery Building. Consider carpooling to save on parking costs.  For a list of campus accessible parking, parking locations, costs and maps visit transportation.wisc.edu

Hotel lodging: Rooms are blocked at two hotels: Wisconsin Union Hotel and DoubleTree by Hilton Madison Downtown. Find hotel details below and click the room block links to reserve before the expiration date.

Wisconsin Union Hotel
1308 W. Dayton Street, Madison, WI 53715
Rate: $192 / night
Parking fee: Included in room rate
Room Block Available until: Oct. 7, 2024
Shuttle: None
Distance to event venue: Across the street
WI Union Hotel room block

DoubleTree by Hilton Madison Downtown
525 W. Johnson Street, Madison, WI 53703
Rate: $169 / night
Parking fee: $18 / day
Room block available until: Oct. 17, 2024
Shuttle: Complimentary conference, downtown, and airport shuttle service
Distance to event venue: 15-minute walk, 7-minute bus, 4-minute car
DoubleTree room block

Eco-friendly conference materials: The conference syllabi are available online (printed copies of materials will not be available). Power points, if released by presenters, will be made available to registered attendees electronically after the conference events. All events will be live and not recorded.

In-person attire: Conference room temperatures may vary, so please plan attire accordingly.

Eco-friendly conference materials

The conference syllabi are available online (printed copies of materials will not be available). Power points, if released by presenters, will be made available on this webpage approximately one week after the conference events. All events will be live and not recorded.